Summary
The global Neurometabolic Disorders Market is expected to witness a CAGR of xx% over the forecast period 2020-2026 and is expected to reach US$ xx million in 2026, from US$ xx million in 2019.
The Neurometabolic Disorders Market report highlights product development and growth strategies such as merger and acquisition adopted by market players along with SWOT Analysis, PEST and Porter’s Five Forces analyses of the Neurometabolic Disorders Market, which highlight the strengths, weaknesses, opportunities, and commination of key companies. Moreover, the report offers two distinct market forecasts, one from the perspective of the producer and another from that of the consumer.
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.
The Key Manufacturers covered in this Report:-
- Amicus Therapeutics
- ISU Abxis
- JCR Pharmaceuticals
- Biosidus
- Greenovation Biotech
- UAB Proforma
- Dong-A Socio Group
- ExSAR Corporation
- Lixte Biotechnology
- Neuraltus Pharmaceuticals
- Protalix
- Pharming Group
- Protalix BioTherapeutics
- Amicus
- Biomarin
- Genzyme
- Shire
- Greencross
By the Product Type, the market is primarily segmented into:
- Gauchers Disease
- Fabry Disease
- Pompe Disease
- Mucopolysaccharidosis VI
- Other
- Market segment by Application, split into
- Oral
- Parenteral
By Applications, the market is segmented into:
The Report covers the following Regions:
- North America
- United States
- Canada
- Mexico
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Central & South America
- Middle East & Africa
- Turkey
- GCC Countries
- Egypt
- South Africa
Objective of the Neurometabolic Disorders Market Report:
- To assess the size of the market by value and volume
- Analyze the Neurometabolic Disorders Market in terms of regions and major countries
- Highlight recent developments and trends in the market
- Offer perceptive data regarding major market players in terms of key developments, strategies, and product portfolio
- Determine share of the Neurometabolic Disorders Market in terms of various segments such as by product type, application, and end-user
- Offer accurate projection of the market for the forecast period using state-of –the-art tools and the current primary and secondary research approaches
- Discuss major factors that impact growth of the Neurometabolic Disorders Market
The Neurometabolic Disorders Market engages the readers with all pivotal approaches to understand their position in the industry based on revenue or sales growth. The report efficiently evaluates the Neurometabolic Disorders Market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competition in the market. The information in the report is backed by annual company reports, financial reports, press releases, regulatory databases, government documents, and statistical databases.
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders:
- Material suppliers/wholesalers
- Market Distributors/traders
- Regulatory bodies
- Research organizations, and consulting firms
- Commercial research & developments (R&D)
- Trade associations and industry bodies
- Importers and exporters
- End-use industries
Available Customizations:
Custom research is one of the most crucial components of the business strategy that helps an organization gain insight into specific business sector, aligned with its specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Neurometabolic Disorders Revenue
1.4 Market Analysis by Type
1.4.1 Global Neurometabolic Disorders Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Gauchers Disease
1.4.3 Fabry Disease
1.4.4 Pompe Disease
1.4.5 Mucopolysaccharidosis VI
1.4.6 Other
1.5 Market by Application
1.5.1 Global Neurometabolic Disorders Market Share by Application: 2020 VS 2026
1.5.2 Oral
1.5.3 Parenteral
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Neurometabolic Disorders Market Perspective (2015-2026)
2.2 Neurometabolic Disorders Growth Trends by Regions
2.2.1 Neurometabolic Disorders Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Neurometabolic Disorders Historic Market Share by Regions (2015-2020)
2.2.3 Neurometabolic Disorders Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porters Five Forces Analysis
2.3.5 Neurometabolic Disorders Market Growth Strategy
2.3.6 Primary Interviews with Key Neurometabolic Disorders Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Neurometabolic Disorders Players by Market Size
3.1.1 Global Top Neurometabolic Disorders Players by Revenue (2015-2020)
3.1.2 Global Neurometabolic Disorders Revenue Market Share by Players (2015-2020)
3.1.3 Global Neurometabolic Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Neurometabolic Disorders Market Concentration Ratio
3.2.1 Global Neurometabolic Disorders Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Neurometabolic Disorders Revenue in 2019
3.3 Neurometabolic Disorders Key Players Head office and Area Served
3.4 Key Players Neurometabolic Disorders Product Solution and Service
3.5 Date of Enter into Neurometabolic Disorders Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Neurometabolic Disorders Historic Market Size by Type (2015-2020)
4.2 Global Neurometabolic Disorders Forecasted Market Size by Type (2021-2026)
5 Neurometabolic Disorders Breakdown Data by Application (2015-2026)
5.1 Global Neurometabolic Disorders Market Size by Application (2015-2020)
5.2 Global Neurometabolic Disorders Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Neurometabolic Disorders Market Size (2015-2020)
6.2 Neurometabolic Disorders Key Players in North America (2019-2020)
6.3 North America Neurometabolic Disorders Market Size by Type (2015-2020)
6.4 North America Neurometabolic Disorders Market Size by Application (2015-2020)
7 Europe
7.1 Europe Neurometabolic Disorders Market Size (2015-2020)
7.2 Neurometabolic Disorders Key Players in Europe (2019-2020)
7.3 Europe Neurometabolic Disorders Market Size by Type (2015-2020)
7.4 Europe Neurometabolic Disorders Market Size by Application (2015-2020)
8 China
8.1 China Neurometabolic Disorders Market Size (2015-2020)
8.2 Neurometabolic Disorders Key Players in China (2019-2020)
8.3 China Neurometabolic Disorders Market Size by Type (2015-2020)
8.4 China Neurometabolic Disorders Market Size by Application (2015-2020)
9 Japan
9.1 Japan Neurometabolic Disorders Market Size (2015-2020)
9.2 Neurometabolic Disorders Key Players in Japan (2019-2020)
9.3 Japan Neurometabolic Disorders Market Size by Type (2015-2020)
9.4 Japan Neurometabolic Disorders Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Neurometabolic Disorders Market Size (2015-2020)
10.2 Neurometabolic Disorders Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Neurometabolic Disorders Market Size by Type (2015-2020)
10.4 Southeast Asia Neurometabolic Disorders Market Size by Application (2015-2020)
11 India
11.1 India Neurometabolic Disorders Market Size (2015-2020)
11.2 Neurometabolic Disorders Key Players in India (2019-2020)
11.3 India Neurometabolic Disorders Market Size by Type (2015-2020)
11.4 India Neurometabolic Disorders Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Neurometabolic Disorders Market Size (2015-2020)
12.2 Neurometabolic Disorders Key Players in Central & South America (2019-2020)
12.3 Central & South America Neurometabolic Disorders Market Size by Type (2015-2020)
12.4 Central & South America Neurometabolic Disorders Market Size by Application (2015-2020)
13Key Players Profiles
13.1 Amicus Therapeutics
13.1.1 Amicus Therapeutics Company Details
13.1.2 Amicus Therapeutics Business Overview and Its Total Revenue
13.1.3 Amicus Therapeutics Neurometabolic Disorders Introduction
13.1.4 Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2015-2020))
13.1.5 Amicus Therapeutics Recent Development
13.2 ISU Abxis
13.2.1 ISU Abxis Company Details
13.2.2 ISU Abxis Business Overview and Its Total Revenue
13.2.3 ISU Abxis Neurometabolic Disorders Introduction
13.2.4 ISU Abxis Revenue in Neurometabolic Disorders Business (2015-2020)
13.2.5 ISU Abxis Recent Development
13.3 JCR Pharmaceuticals
13.3.1 JCR Pharmaceuticals Company Details
13.3.2 JCR Pharmaceuticals Business Overview and Its Total Revenue
13.3.3 JCR Pharmaceuticals Neurometabolic Disorders Introduction
13.3.4 JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2015-2020)
13.3.5 JCR Pharmaceuticals Recent Development
13.4 Biosidus
13.4.1 Biosidus Company Details
13.4.2 Biosidus Business Overview and Its Total Revenue
13.4.3 Biosidus Neurometabolic Disorders Introduction
13.4.4 Biosidus Revenue in Neurometabolic Disorders Business (2015-2020)
13.4.5 Biosidus Recent Development
13.5 Greenovation Biotech
13.5.1 Greenovation Biotech Company Details
13.5.2 Greenovation Biotech Business Overview and Its Total Revenue
13.5.3 Greenovation Biotech Neurometabolic Disorders Introduction
13.5.4 Greenovation Biotech Revenue in Neurometabolic Disorders Business (2015-2020)
13.5.5 Greenovation Biotech Recent Development
13.6 UAB Proforma
13.6.1 UAB Proforma Company Details
13.6.2 UAB Proforma Business Overview and Its Total Revenue
13.6.3 UAB Proforma Neurometabolic Disorders Introduction
13.6.4 UAB Proforma Revenue in Neurometabolic Disorders Business (2015-2020)
13.6.5 UAB Proforma Recent Development
13.7 Dong-A Socio Group
13.7.1 Dong-A Socio Group Company Details
13.7.2 Dong-A Socio Group Business Overview and Its Total Revenue
13.7.3 Dong-A Socio Group Neurometabolic Disorders Introduction
13.7.4 Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2015-2020)
13.7.5 Dong-A Socio Group Recent Development
13.8 ExSAR Corporation
13.8.1 ExSAR Corporation Company Details
13.8.2 ExSAR Corporation Business Overview and Its Total Revenue
13.8.3 ExSAR Corporation Neurometabolic Disorders Introduction
13.8.4 ExSAR Corporation Revenue in Neurometabolic Disorders Business (2015-2020)
13.8.5 ExSAR Corporation Recent Development
13.9 Lixte Biotechnology
13.9.1 Lixte Biotechnology Company Details
13.9.2 Lixte Biotechnology Business Overview and Its Total Revenue
13.9.3 Lixte Biotechnology Neurometabolic Disorders Introduction
13.9.4 Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2015-2020)
13.9.5 Lixte Biotechnology Recent Development
13.10 Neuraltus Pharmaceuticals
13.10.1 Neuraltus Pharmaceuticals Company Details
13.10.2 Neuraltus Pharmaceuticals Business Overview and Its Total Revenue
13.10.3 Neuraltus Pharmaceuticals Neurometabolic Disorders Introduction
13.10.4 Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2015-2020)
13.10.5 Neuraltus Pharmaceuticals Recent Development
13.11 Protalix
10.11.1 Protalix Company Details
10.11.2 Protalix Business Overview and Its Total Revenue
10.11.3 Protalix Neurometabolic Disorders Introduction
10.11.4 Protalix Revenue in Neurometabolic Disorders Business (2015-2020)
10.11.5 Protalix Recent Development
13.12 Pharming Group
10.12.1 Pharming Group Company Details
10.12.2 Pharming Group Business Overview and Its Total Revenue
10.12.3 Pharming Group Neurometabolic Disorders Introduction
10.12.4 Pharming Group Revenue in Neurometabolic Disorders Business (2015-2020)
10.12.5 Pharming Group Recent Development
13.13 Protalix BioTherapeutics
10.13.1 Protalix BioTherapeutics Company Details
10.13.2 Protalix BioTherapeutics Business Overview and Its Total Revenue
10.13.3 Protalix BioTherapeutics Neurometabolic Disorders Introduction
10.13.4 Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2015-2020)
10.13.5 Protalix BioTherapeutics Recent Development
13.14 Amicus
10.14.1 Amicus Company Details
10.14.2 Amicus Business Overview and Its Total Revenue
10.14.3 Amicus Neurometabolic Disorders Introduction
10.14.4 Amicus Revenue in Neurometabolic Disorders Business (2015-2020)
10.14.5 Amicus Recent Development
13.15 Biomarin
10.15.1 Biomarin Company Details
10.15.2 Biomarin Business Overview and Its Total Revenue
10.15.3 Biomarin Neurometabolic Disorders Introduction
10.15.4 Biomarin Revenue in Neurometabolic Disorders Business (2015-2020)
10.15.5 Biomarin Recent Development
13.16 Genzyme
10.16.1 Genzyme Company Details
10.16.2 Genzyme Business Overview and Its Total Revenue
10.16.3 Genzyme Neurometabolic Disorders Introduction
10.16.4 Genzyme Revenue in Neurometabolic Disorders Business (2015-2020)
10.16.5 Genzyme Recent Development
13.17 Shire
10.17.1 Shire Company Details
10.17.2 Shire Business Overview and Its Total Revenue
10.17.3 Shire Neurometabolic Disorders Introduction
10.17.4 Shire Revenue in Neurometabolic Disorders Business (2015-2020)
10.17.5 Shire Recent Development
13.18 Greencross
10.18.1 Greencross Company Details
10.18.2 Greencross Business Overview and Its Total Revenue
10.18.3 Greencross Neurometabolic Disorders Introduction
10.18.4 Greencross Revenue in Neurometabolic Disorders Business (2015-2020)
10.18.5 Greencross Recent Development
14Analyst's Viewpoints/Conclusions
15Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
List of Table
List of Tables
Table 1. Neurometabolic Disorders Key Market Segments
Table 2. Key Players Covered: Ranking by Neurometabolic Disorders Revenue
Table 3. Ranking of Global Top Neurometabolic Disorders Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Neurometabolic Disorders Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Gauchers Disease
Table 6. Key Players of Fabry Disease
Table 7. Key Players of Pompe Disease
Table 8. Key Players of Mucopolysaccharidosis VI
Table 9. Key Players of Other
Table 10. Global Neurometabolic Disorders Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Neurometabolic Disorders Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Neurometabolic Disorders Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Neurometabolic Disorders Market Share by Regions (2015-2020)
Table 14. Global Neurometabolic Disorders Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Neurometabolic Disorders Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Neurometabolic Disorders Market Growth Strategy
Table 20. Main Points Interviewed from Key Neurometabolic Disorders Players
Table 21. Global Neurometabolic Disorders Revenue by Players (2015-2020) (Million US$)
Table 22. Global Neurometabolic Disorders Market Share by Players (2015-2020)
Table 23. Global Top Neurometabolic Disorders Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurometabolic Disorders as of 2019)
Table 24. Global Neurometabolic Disorders by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Neurometabolic Disorders Product Solution and Service
Table 27. Date of Enter into Neurometabolic Disorders Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Neurometabolic Disorders Market Size by Type (2015-2020) (Million US$)
Table 30. Global Neurometabolic Disorders Market Size Share by Type (2015-2020)
Table 31. Global Neurometabolic Disorders Revenue Market Share by Type (2021-2026)
Table 32. Global Neurometabolic Disorders Market Size Share by Application (2015-2020)
Table 33. Global Neurometabolic Disorders Market Size by Application (2015-2020) (Million US$)
Table 34. Global Neurometabolic Disorders Market Size Share by Application (2021-2026)
Table 35. North America Key Players Neurometabolic Disorders Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Neurometabolic Disorders Market Share (2019-2020)
Table 37. North America Neurometabolic Disorders Market Size by Type (2015-2020) (Million US$)
Table 38. North America Neurometabolic Disorders Market Share by Type (2015-2020)
Table 39. North America Neurometabolic Disorders Market Size by Application (2015-2020) (Million US$)
Table 40. North America Neurometabolic Disorders Market Share by Application (2015-2020)
Table 41. Europe Key Players Neurometabolic Disorders Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Neurometabolic Disorders Market Share (2019-2020)
Table 43. Europe Neurometabolic Disorders Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Neurometabolic Disorders Market Share by Type (2015-2020)
Table 45. Europe Neurometabolic Disorders Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Neurometabolic Disorders Market Share by Application (2015-2020)
Table 47. China Key Players Neurometabolic Disorders Revenue (2019-2020) (Million US$)
Table 48. China Key Players Neurometabolic Disorders Market Share (2019-2020)
Table 49. China Neurometabolic Disorders Market Size by Type (2015-2020) (Million US$)
Table 50. China Neurometabolic Disorders Market Share by Type (2015-2020)
Table 51. China Neurometabolic Disorders Market Size by Application (2015-2020) (Million US$)
Table 52. China Neurometabolic Disorders Market Share by Application (2015-2020)
Table 53. Japan Key Players Neurometabolic Disorders Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Neurometabolic Disorders Market Share (2019-2020)
Table 55. Japan Neurometabolic Disorders Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Neurometabolic Disorders Market Share by Type (2015-2020)
Table 57. Japan Neurometabolic Disorders Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Neurometabolic Disorders Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Neurometabolic Disorders Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Neurometabolic Disorders Market Share (2019-2020)
Table 61. Southeast Asia Neurometabolic Disorders Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Neurometabolic Disorders Market Share by Type (2015-2020)
Table 63. Southeast Asia Neurometabolic Disorders Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Neurometabolic Disorders Market Share by Application (2015-2020)
Table 65. India Key Players Neurometabolic Disorders Revenue (2019-2020) (Million US$)
Table 66. India Key Players Neurometabolic Disorders Market Share (2019-2020)
Table 67. India Neurometabolic Disorders Market Size by Type (2015-2020) (Million US$)
Table 68. India Neurometabolic Disorders Market Share by Type (2015-2020)
Table 69. India Neurometabolic Disorders Market Size by Application (2015-2020) (Million US$)
Table 70. India Neurometabolic Disorders Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Neurometabolic Disorders Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Neurometabolic Disorders Market Share (2019-2020)
Table 73. Central & South America Neurometabolic Disorders Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Neurometabolic Disorders Market Share by Type (2015-2020)
Table 75. Central & South America Neurometabolic Disorders Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Neurometabolic Disorders Market Share by Application (2015-2020)
Table 77. Amicus Therapeutics Company Details
Table 78. Amicus Therapeutics Business Overview
Table 79. Amicus Therapeutics Product
Table 80. Amicus Therapeutics Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 81. Amicus Therapeutics Recent Development
Table 82. ISU Abxis Company Details
Table 83. ISU Abxis Business Overview
Table 84. ISU Abxis Product
Table 85. ISU Abxis Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 86. ISU Abxis Recent Development
Table 87. JCR Pharmaceuticals Company Details
Table 88. JCR Pharmaceuticals Business Overview
Table 89. JCR Pharmaceuticals Product
Table 90. JCR Pharmaceuticals Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 91. JCR Pharmaceuticals Recent Development
Table 92. Biosidus Company Details
Table 93. Biosidus Business Overview
Table 94. Biosidus Product
Table 95. Biosidus Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 96. Biosidus Recent Development
Table 97. Greenovation Biotech Company Details
Table 98. Greenovation Biotech Business Overview
Table 99. Greenovation Biotech Product
Table 100. Greenovation Biotech Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 101. Greenovation Biotech Recent Development
Table 102. UAB Proforma Company Details
Table 103. UAB Proforma Business Overview
Table 104. UAB Proforma Product
Table 105. UAB Proforma Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 106. UAB Proforma Recent Development
Table 107. Dong-A Socio Group Company Details
Table 108. Dong-A Socio Group Business Overview
Table 109. Dong-A Socio Group Product
Table 110. Dong-A Socio Group Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 111. Dong-A Socio Group Recent Development
Table 112. ExSAR Corporation Business Overview
Table 113. ExSAR Corporation Product
Table 114. ExSAR Corporation Company Details
Table 115. ExSAR Corporation Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 116. ExSAR Corporation Recent Development
Table 117. Lixte Biotechnology Company Details
Table 118. Lixte Biotechnology Business Overview
Table 119. Lixte Biotechnology Product
Table 120. Lixte Biotechnology Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 121. Lixte Biotechnology Recent Development
Table 122. Neuraltus Pharmaceuticals Company Details
Table 123. Neuraltus Pharmaceuticals Business Overview
Table 124. Neuraltus Pharmaceuticals Product
Table 125. Neuraltus Pharmaceuticals Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 126. Neuraltus Pharmaceuticals Recent Development
Table 127. Protalix Company Details
Table 128. Protalix Business Overview
Table 129. Protalix Product
Table 130. Protalix Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 131. Protalix Recent Development
Table 132. Pharming Group Company Details
Table 133. Pharming Group Business Overview
Table 134. Pharming Group Product
Table 135. Pharming Group Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 136. Pharming Group Recent Development
Table 137. Protalix BioTherapeutics Company Details
Table 138. Protalix BioTherapeutics Business Overview
Table 139. Protalix BioTherapeutics Product
Table 140. Protalix BioTherapeutics Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 141. Protalix BioTherapeutics Recent Development
Table 142. Amicus Company Details
Table 143. Amicus Business Overview
Table 144. Amicus Product
Table 145. Amicus Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 146. Amicus Recent Development
Table 147. Biomarin Company Details
Table 148. Biomarin Business Overview
Table 149. Biomarin Product
Table 150. Biomarin Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 151. Biomarin Recent Development
Table 152. Genzyme Company Details
Table 153. Genzyme Business Overview
Table 154. Genzyme Product
Table 155. Genzyme Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 156. Genzyme Recent Development
Table 157. Shire Company Details
Table 158. Shire Business Overview
Table 159. Shire Product
Table 160. Shire Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 161. Shire Recent Development
Table 162. Greencross Company Details
Table 163. Greencross Business Overview
Table 164. Greencross Product
Table 165. Greencross Revenue in Neurometabolic Disorders Business (2015-2020) (Million US$)
Table 166. Greencross Recent Development
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurometabolic Disorders Market Share by Type: 2020 VS 2026
Figure 2. Gauchers Disease Features
Figure 3. Fabry Disease Features
Figure 4. Pompe Disease Features
Figure 5. Mucopolysaccharidosis VI Features
Figure 6. Other Features
Figure 7. Global Neurometabolic Disorders Market Share by Application: 2020 VS 2026
Figure 8. Oral Case Studies
Figure 9. Parenteral Case Studies
Figure 10. Neurometabolic Disorders Report Years Considered
Figure 11. Global Neurometabolic Disorders Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Neurometabolic Disorders Market Share by Regions: 2020 VS 2026
Figure 13. Global Neurometabolic Disorders Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Neurometabolic Disorders Market Share by Players in 2019
Figure 16. Global Top Neurometabolic Disorders Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurometabolic Disorders as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Neurometabolic Disorders Revenue in 2019
Figure 18. North America Neurometabolic Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Neurometabolic Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Neurometabolic Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Neurometabolic Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Neurometabolic Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Neurometabolic Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Neurometabolic Disorders Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Amicus Therapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Amicus Therapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 27. ISU Abxis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. ISU Abxis Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 29. JCR Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. JCR Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 31. Biosidus Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Biosidus Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 33. Greenovation Biotech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Greenovation Biotech Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 35. UAB Proforma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. UAB Proforma Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 37. Dong-A Socio Group Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Dong-A Socio Group Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 39. ExSAR Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. ExSAR Corporation Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 41. Lixte Biotechnology Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Lixte Biotechnology Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 43. Neuraltus Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Neuraltus Pharmaceuticals Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 45. Protalix Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Protalix Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 47. Pharming Group Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Pharming Group Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 49. Protalix BioTherapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Protalix BioTherapeutics Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 51. Amicus Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Amicus Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 53. Biomarin Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Biomarin Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 55. Genzyme Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Genzyme Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 57. Shire Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Shire Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 59. Greencross Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Greencross Revenue Growth Rate in Neurometabolic Disorders Business (2015-2020)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Request Discount 
Inquire Before Buy
